Health ❯ Healthcare ❯ Patient Care ❯ Treatment Efficacy

Safety and Tolerability

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

The company is targeting second-half 2026 global submissions after reporting a consistent safety profile.

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses